12/10/2017 20:28:02

LexaGene unaware of any material change

VANCOUVER, British Columbia, Oct. 12, 2017 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), at the request of IIROC, LexaGene Holdings Inc. wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

We are still on track and excited for completing the LX6 Alpha prototype by the end of November.

About LexaGene Holdings Inc.

LexaGene is a biotechnology company developing the very first fully automated pathogen detection platform that is open-access.  The open-access feature will empower end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection.  End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The instrument is expected to offer excellent sensitivity, specificity, and breadth of pathogen detection.  The instrument will be able to process six samples at a time, in an on-demand fashion, returning results in about 1 hour.  The company expects to sell its technology in the food safety, veterinary diagnostics, water quality monitoring, and aquaculture pathogen surveillance markets.

To be added to the LexaGene email distribution list, please subscribe on the LexaGene website here.

ON BEHALF OF THE BOARD “Jack Regan”

Dr. Jack Regan: Founder, Chief Executive Officer, and Director

For further information, please contact:

Caitlin Kasunich (ckasunich@kcsa.com)  

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see 

www.sedar.com

). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact

Caitlin Kasunich

KCSA Strategic Communications

212.896.1241

ckasunich@kcsa.com 

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Feb
PNDORA
  Jeg har gentagne gange analyseret Pandora. Læsere, som ønsker mine analyse af Pandoras forretnings..
80
10 Feb
I:SP500
Hejsa alle sammen   Så er det vinterferie og hvad kan tiden bruges til, ja lidt teknisk på stockmark..
36
13 Feb
 
Lad dog Henrik dø i fred i stedet for at komme med jeres dumsmarte bemærkninger   Det er upazsende u..
28
16 Feb
NOVO-B
@ Investor1 Jeg er hverken for eller imod hvad du skriver, men jeg har nu i gennem næsten et år løbe..
26
11 Feb
I:SP500
Prisdannelsen over S&P 500 med anvendelsen af candelstik med en månedlig tidsramme:   https://invst...
24
16 Feb
NOVO-B
Din og Investor1's totale fejlvurdering af både Zealand og Novo har desværre udviklet sig til et per..
19
15 Feb
OMXC20
Kære alle. Jeg har flere gange tilbudt at svare på investeringsspørgsmål for at bidrage til at så ma..
19
13 Feb
 
nu syntes jeg i er for åndsvage manden er ved at dø forhelvede
18
10 Feb
PNDORA
Jeg forstår ikke, hvordan man kan være så blæst i hovedet, som du er.
18
12 Feb
FING-B
Fjols
17

Elliott Capital Advisors, L.P : Form 8.3 - MELROSE INDUSTRIES PLC

16/02/2018 15:25:32
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners an..

Cisco Offers Cloud-Based Endpoint Security Solutions for Managed Security Service Providers

16/02/2018 13:00:19
Cisco's comprehensive cloud-based security endpoint portfolio provides advanced malware protection, internet security, and enterprise mobility management   SAN JOSE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Cisco today is helping address the challenges of Managed Security Service Providers (MSSP) and their customers by offering MSSPs comprehensive security, visibility, and control of cu..

Boussard & Gavaudan Investment Management LLP : Form 8.3 - UBM plc

16/02/2018 10:19:24
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a)  Identity of the person whose positions/dealings are being disclosed: Boussard & Gavaudan Investment Manage..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
PHOTO RELEASE--Huntington Ingalls Industries Awarded $1.43 Billion Contract For The Construction of LPD 29
2
Emerald Health, Strategic Majority Investor in Nemus Bioscience, Completes Final Closing of Private Placement Investment Ahead of Schedule
3
QUANTUM CORPORATION SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Quantum Corporation - QTM
4
WELLS FARGO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Wells Fargo & Company - WFC
5
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Obalon Therapeutics, Inc. (OBLN)

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
17 February 2018 19:15:34
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180209.1 - EUROWEB4 - 2018-02-17 20:15:34 - 2018-02-17 19:15:34 - 1000 - Website: OKAY